This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
by Zacks Equity Research
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
by Zacks Equity Research
The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease in adults.
Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
by Zacks Equity Research
Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer
by Zacks Equity Research
The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based on ADRIATIC study data.
Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?
by Zacks Equity Research
BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
by Zacks Equity Research
Novo Nordisk, Roche, Pfizer, Arvinas and J&J are part of the Zacks top Analyst Blog.
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
by Kinjel Shah
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.
AMRN's Q4 Earnings Lag Estimates, Stock Down on Ratio Change Plan
by Zacks Equity Research
Amarin incurs a wider-than-expected loss in Q4. Revenues beat estimates. It plans to initiate a ratio change on its American Depositary Shares. Stock falls.
Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?
by Zacks Equity Research
Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
by Ekta Bagri
TSVT and PTGX are in the spotlight this week following an acquisition agreement and study data, respectively.
ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study
by Zacks Equity Research
Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.
Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 228.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy
by Zacks Equity Research
Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%
by Zacks Equity Research
The mean of analysts' price targets for Arvinas (ARVN) points to a 235.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arvinas (ARVN) delivered earnings and revenue surprises of 41.12% and 4.65%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas (ARVN) delivered earnings and revenue surprises of 22.73% and 45.09%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?
by Zacks Equity Research
Novartis' (NVS) efforts to ward off generic competition for its top cardiovascular drug, Entresto, face a setback.
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas (ARVN) delivered earnings and revenue surprises of 31.94% and 20.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View
by Zacks Equity Research
Novartis' (NVS) second-quarter earnings and sales beat estimates. Based on strong momentum, the company raises its operating income outlook for 2024.
Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Arvinas (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?
by Zacks Equity Research
Cytek Biosciences (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Acadia (ACHC), Geisinger JV Begin Construction of New Hospital
by Zacks Equity Research
The new hospital from Acadia (ACHC) and Geisinger JV is scheduled to open in spring 2025.
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arvinas (ARVN) delivered earnings and revenue surprises of 34.46% and 18.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?